The Amplatzer muscular VSD occluder was approved by the Food and Drug Administration
in 2007 and is currently the only device approved for VSD closure in the United States. The …

This review discusses the management of ventricular septal defects (VSDs) and
atrioventricular septal defects (AVSDs). There are several types of VSDs: perimembranous …

Aim To report the experience of 23 tertiary referral European Centres on transcatheter
closure of congenital ventricular septal defects (VSD). Methods and results Implantation of …

Objectives: We sought to analyze safety, efficacy, and follow-up results of percutaneous
closure of perimembranous ventricular septal defects (pmVSD). Background: Results of …

Objectives: This phase I study attempted to report the initial safety and efficacy results of
transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using the new …

Objective: To report the immediate and midterm results of transcatheter closure of
perimembranous ventricular septal defect (PmVSD) using the Amplatzer membranous VSD …

Background While transcatheter device closure of ventricular septal defects (VSDs) is
gaining popularity, concerns remain about adverse events; particularly heart block in peri …

This study reports on experience with transcatheter closure of congenital ventricular septal
defects (VSDs) with Amplatzer septal occluders. From January 2000 to April 2005 …

Percutaneous closure of perimembranous ventricular septal defects (VSDs) has been
feasible, safe, and effective with the new Amplatzer membranous septal occluder. We report …

Objective: To look at the presentation, treatment and outcome of patients who developed
atrioventricular block after transcatheter closure of a perimembranous ventricular septal …